Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carthadex trial in newly diagnosed transplant-eligible multiple myeloma
NL-OMON25987Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carfilzomib, thalidomide and dexamethasone in multiple myeloma (MM), sponsored by Erasmus MC. Primary endpoints: Response after induction prior to HDM/ASCT, Response after HDM/ASCT prior to consolidation and 1 more. Planned start Jul 2010; status: not yet recruiting.
02
Drugs
carfilzomibthalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON25987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25987.